ARCHIVES

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

This article is from The Cancer Letter archive.

Vol. 23 No. 37 | September 26, 1997

Download PDF Visit The Full Archive

Related Articles

Phase II Elotuzumab Study Demonstrates 33 Months PFS

July 26, 2013

Sept. 9 NCAB Meeting: Varmus: Expect Another CR For Funding The NIH Through Mid-December

September 19, 2014

Coffey Presses NCI BSA chairman David Linvingston On support For Increase In NCI Budget

April 25, 1997

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

WETA Relents Will Air Documentary

April 10, 1987

Drug Approvals: FDA grants accelerated approval for Keytruda in metastatic melanoma

September 5, 2014